Company performance
Add to research
Current Price
as of Mar 21, 2025$36.96
P/E Ratio
21.12
Market Cap
$10.34B
Description
Add to research
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Metrics
Add to research
Overview
- HQAlameda, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerEXEL
- Price$36.96-0.59%
Trading Information
- Market cap$10.34B
- Float97.12%
- Average Daily Volume (1m)2,915,121
- Average Daily Volume (3m)2,592,423
- EPS$1.80
Company
- Revenue$2.17B
- Rev growth (1yr)18.49%
- Net income$521.27M
- Gross margin96.49%
- EBITDA margin33.14%
- EBITDA$718.75M
- EV$9.12B
- EV/Revenue4.20
- P/E21.12
- P/S5.08
- P/B4.67
- Debt/Equity9.62
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Factset